A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ...

Astrazeneca's EVP – International shares how the company is working to deliver healthcare that is inclusive, impactful and ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...

The facility, which will produce cell therapies used to treat cancer and auto immune diseases, creates 150 jobs for highly ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to ...

Astrazeneca (AZN) closed the last trading session at $67.30, gaining 3.8% over the past four weeks, but there could be plenty ...